BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37978023)

  • 21. [Comprehensive therapy of bladder preservation for muscle invasive bladder cancer].
    Li B; Li Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 43(1):82-89. PubMed ID: 30154296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bladder-sparing treatment of invasive bladder cancer.
    Rivera I; Wajsman Z
    Cancer Control; 2000; 7(4):340-6. PubMed ID: 10895128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
    Mitin T; George A; Zietman AL; Heney NM; Kaufman DS; Uzzo RG; Dreicer R; Wallace HJ; Souhami L; Dobelbower MC; Sandler HM; Shipley WU
    Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):67-74. PubMed ID: 26700703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.
    Zhong J; Switchenko J; Jegadeesh NK; Cassidy RJ; Gillespie TW; Master V; Nieh P; Alemozaffar M; Kucuk O; Carthon B; Filson CP; Bilen MA; Jani AB
    Am J Clin Oncol; 2019 Jan; 42(1):36-41. PubMed ID: 29912804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.
    Jiang DM; Chung P; Kulkarni GS; Sridhar SS
    Curr Oncol Rep; 2020 Feb; 22(2):14. PubMed ID: 32008105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection.
    Liang S; Zou Q; Han B; Jing Y; Cui D; An X; Gao Y; Hu J; Xia S
    Urol Int; 2015; 94(4):406-11. PubMed ID: 25678415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
    García-Perdomo HA; Montes-Cardona CE; Guacheta M; Castillo DF; Reis LO
    World J Urol; 2018 Dec; 36(12):1997-2008. PubMed ID: 29943218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
    Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
    Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
    Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients With Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-matched Study.
    Bai S; Yao Z; Zhu X; Li Z; Jiang Y; Wang R; Wen N
    Urology; 2019 Mar; 125():138-145. PubMed ID: 30445122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term Outcomes and Patterns of Failure Following Trimodality Treatment With Bladder Preservation for Invasive Bladder Cancer.
    Büchser D; Zapatero A; Rogado J; Talaya M; Martín de Vidales C; Arellano R; Bocardo G; Cruz Conde A; Pérez L; Murillo MT
    Urology; 2019 Feb; 124():183-190. PubMed ID: 30266376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
    Montorsi F; Rosiello G; Gandaglia G; Salonia A; Briganti A
    Eur Urol Oncol; 2024 Jun; 7(3):636. PubMed ID: 37951819
    [No Abstract]   [Full Text] [Related]  

  • 36. Robot-assisted radical cystectomy: description of an evolved approach to radical cystectomy.
    Collins JW; Tyritzis S; Nyberg T; Schumacher M; Laurin O; Khazaeli D; Adding C; Jonsson MN; Hosseini A; Wiklund NP
    Eur Urol; 2013 Oct; 64(4):654-63. PubMed ID: 23769588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invasive T1 bladder cancer: indications and rationale for radical cystectomy.
    Stein JP; Penson DF
    BJU Int; 2008 Aug; 102(3):270-5. PubMed ID: 18494831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of bladder preservation therapy on survival in patients with muscle-invasive bladder cancer.
    Özaydın Ş; Ataş E; Karadurmuş N; Emirzeoğlu L; Arpacı F
    Arch Esp Urol; 2020 Jan; 73(1):41-46. PubMed ID: 31950922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
    Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
    Huddart RA; Birtle A; Maynard L; Beresford M; Blazeby J; Donovan J; Kelly JD; Kirkbank T; McLaren DB; Mead G; Moynihan C; Persad R; Scrase C; Lewis R; Hall E
    BJU Int; 2017 Nov; 120(5):639-650. PubMed ID: 28453896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.